InsiderTrades

Form 4 for ANTX AN2 Therapeutics, Inc.

Accepted 2022-03-31 00:00:00 ET · period of report 2022-03-29 · accession 0001104659-22-041080 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMI 2022-03-31 2022-03-29 ANTX Kolchinsky Peter 10% P - Purchase $15.00 +1.67M 3.25M +105% +$25.00M
DMI 2022-03-31 2022-03-29 ANTX Kolchinsky Peter 10% C - Cnv Deriv — +2.00M 1.70M New —
DMI 2022-03-31 2022-03-29 ANTX Kolchinsky Peter 10% C - Cnv Deriv $0.00 -2.00M 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-03-29 P A 115,613 $15.00 415,612 I See Footnotes — — (F3) These securities are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
2 Common Common Stock 2022-03-29 C A 299,999 — 299,999 I See Footnotes — — (F1) On March 29, 2022, each share of Series B Preferred Stock (the "Preferred Stock") converted into Common Stock of the Issuer at a ratio of 1-for-1 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. (F3) These securities are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
3 Common Common Stock 2022-03-29 C A 1,699,998 — 1,699,998 I See Footnotes — — (F1) On March 29, 2022, each share of Series B Preferred Stock (the "Preferred Stock") converted into Common Stock of the Issuer at a ratio of 1-for-1 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. (F2) These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
4 Common Common Stock 2022-03-29 P A 1,551,053 $15.00 3,251,051 I See Footnotes — — (F2) These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
5 Derivative Series B Preferred Stock 2022-03-29 C D 299,999 $0.00 0 I See footnotes — · — to — 299,999 Common Stock (F3) These securities are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F1) On March 29, 2022, each share of Series B Preferred Stock (the "Preferred Stock") converted into Common Stock of the Issuer at a ratio of 1-for-1 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
6 Derivative Series B Preferred Stock 2022-03-29 C D 1,699,998 $0.00 0 I See footnotes — · — to — 1,699,998 Common Stock (F4) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F2) These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). (F1) On March 29, 2022, each share of Series B Preferred Stock (the "Preferred Stock") converted into Common Stock of the Issuer at a ratio of 1-for-1 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.